Sage Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-400.67	-541.49	-532.78	-457.89	606.07	Upgrade
Depreciation & Amortization	1.03	1.39	1.12	4.18	2.63	Upgrade
Loss (Gain) From Sale of Investments	-6.83	-6.47	4.35	-10.6	-0.69	Upgrade
Stock-Based Compensation	54.5	73.37	61.6	104.63	95.99	Upgrade
Change in Accounts Payable	2.38	-8.5	8.43	6.69	-11.51	Upgrade
Change in Other Net Operating Assets	82.38	-58.89	-2.76	-25.2	-28.22	Upgrade
Operating Cash Flow	-267.19	-540.59	-460.04	-378.18	664.28	Upgrade
Capital Expenditures	-	-0.55	-0.94	-0.37	-0.35	Upgrade
Investment in Securities	266.68	443.47	326.37	-1,002	443.03	Upgrade
Investing Cash Flow	266.68	442.91	325.43	-1,002	442.68	Upgrade
Issuance of Common Stock	11.18	6.93	3.11	14.72	426.76	Upgrade
Repurchase of Common Stock	-0.4	-0.9	-0.04	-1.39	-	Upgrade
Other Financing Activities	-0.12	-	-	-	-	Upgrade
Financing Cash Flow	10.66	6.03	3.07	13.33	426.76	Upgrade
Net Cash Flow	10.15	-91.65	-131.53	-1,367	1,534	Upgrade
Free Cash Flow	-267.19	-541.14	-460.97	-378.55	663.94	Upgrade
Free Cash Flow Margin	-647.85%	-625.92%	-5997.57%	-6001.17%	59.59%	Upgrade
Free Cash Flow Per Share	-4.40	-9.04	-7.77	-6.45	12.53	Upgrade
Levered Free Cash Flow	-119.04	-333.05	-272.33	-195.97	448.8	Upgrade
Unlevered Free Cash Flow	-119.04	-333.05	-272.33	-195.97	448.8	Upgrade
Change in Net Working Capital	-82	65.71	-7.75	16.34	39.46	Upgrade

Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q